SCM
Stonepine Capital Management Portfolio holdings
AUM
$102M
This Quarter Return
+8.55%
1 Year Return
+40.04%
3 Year Return
+160.28%
5 Year Return
+195.28%
10 Year Return
–
AUM
$102M
AUM Growth
+$102M
(-1.2%)
Cap. Flow
-$3.93M
Cap. Flow
% of AUM
-3.88%
Top 10 Holdings %
Top 10 Hldgs %
59.23%
Holding
86
New
20
Increased
24
Reduced
14
Closed
28
Top Buys
| 1 |
Verastem
VSTM
|
$3.1M |
| 2 |
Acadia Pharmaceuticals
ACAD
|
$2.84M |
| 3 |
Ardelyx
ARDX
|
$2.18M |
| 4 |
iTeos Therapeutics
ITOS
|
$1.99M |
| 5 |
Nektar Therapeutics
NKTR
|
$1.3M |
Top Sells
| 1 |
OPTN
OptiNose
OPTN
|
$7.23M |
| 2 |
UroGen Pharma
URGN
|
$3.69M |
| 3 |
Aquestive Therapeutics
AQST
|
$3.04M |
| 4 |
Establishment Labs
ESTA
|
$2.88M |
| 5 |
Galapagos
GLPG
|
$2.36M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
ADMA Biologics
ADMA
$4.12B
| $13.7M | 13.4% | 750,000 -60,000 | -7% | -$1.09M |
|
2
Evolus
EOLS
$494M
| $8.44M | 8.28% | 916,500 -218,074 | -19% | -$2.01M |
|
3
Zevra Therapeutics
ZVRA
$509M
| $6.83M | 6.7% | 775,620 +125,620 | +19% | +$1.11M |
|
|
4
Verastem
VSTM
$569M
| $5.65M | 5.54% | 1,360,386 +747,386 | +122% | +$3.1M |
|
5
Indivior
INDV
$3.03B
| $5.16M | 5.06% | 350,000 +46,000 | +15% | +$678K |
|
|
6
Acadia Pharmaceuticals
ACAD
$4.38B
| $4.85M | 4.76% | 225,000 +131,607 | +141% | +$2.84M |
|
7
Enanta Pharmaceuticals
ENTA
$180M
| $4.57M | 4.48% | 604,066 +13,324 | +2% | +$101K |
|
8
TELA Bio
TELA
$70.5M
| $4.04M | 3.97% | 2,083,762 +28,537 | +1% | +$55.4K |
|
9
Xoma
XOMA
$392M
| $3.83M | 3.76% | 152,143 +22,330 | +17% | +$563K |
|
|
10
iTeos Therapeutics
ITOS
| $3.09M | 3.03% | 310,033 +200,033 | +182% | +$1.99M |
|
11
Day One Biopharmaceuticals
DAWN
$769M
| $2.93M | 2.87% | 450,000 +101,180 | +29% | +$658K |
|
12
Surrozen
SRZN
$104M
| $2.74M | 2.68% | 306,029 +20,247 | +7% | +$181K |
|
13
ANI Pharmaceuticals
ANIP
$2.03B
| $2.52M | 2.47% | 38,597 -9,403 | -20% | -$614K |
|
|
14
Ardelyx
ARDX
$1.53B
| $2.18M | 2.13% | +555,000 | New | +$2.18M |
|
15
Anika Therapeutics
ANIK
$135M
| $2.02M | 1.98% | 190,590 -16,049 | -8% | -$170K |
|
16
AYTU BioPharma
AYTU
$21.1M
| $1.77M | 1.74% | 812,676 +348,955 | +75% | +$761K |
|
17
Inhibikase Therapeutics
IKT
$134M
| $1.43M | 1.4% | 733,793 -181,180 | -20% | -$353K |
|
18
Geron
GERN
$893M
| $1.41M | 1.38% | 1,000,000 +500,000 | +100% | +$705K |
|
19
Heron Therapeutics
HRTX
$207M
| $1.36M | 1.34% | 657,380 -138,720 | -17% | -$287K |
|
|
20
Nektar Therapeutics
NKTR
$568M
| $1.3M | 1.27% | +50,200 | New | +$1.3M |
|
21
Y-mAbs Therapeutics
YMAB
$388M
| $1.29M | 1.26% | 285,300 +154,140 | +118% | +$695K |
|
22
Collegium Pharmaceutical
COLL
$1.22B
| $1.23M | 1.2% | 41,500 +20,893 | +101% | +$618K |
|
23
Vanda Pharmaceuticals
VNDA
$279M
| $1.18M | 1.16% | 250,000 +214,852 | +611% | +$1.01M |
|
24
KalVista Pharmaceuticals
KALV
$678M
| $1.13M | 1.11% | 100,000 +78,450 | +364% | +$887K |
|
|
ALMS
25
Alumis Inc. Common Stock
ALMS
$479M
| $1.05M | 1.03% | +349,615 | New | +$1.05M |
|